ended 30 June 2017 which has been reviewed by auditor as follows: Table1: Financial Summary for the three-month of year 2016 and 2017 Unit: Million Baht Q2’2017 Q2’2016 Increase (Decrease) % Change Sales
Ramnakara Co.,Ltd.'s capital increase shares and status change from Associated to Subsidiary. 09/06/2022 17:01 The acquisition of investment in Vachara Sirivej Co.,Ltd. (Chiangrai Inter Hospital) 07/06/2022
of operating results for the year 2019, Ended of December 31, 2019 Unit : Million Baht Power Generation Others Total Change Increase (Decrease) 2019 2018 2019 2018 2019 2018 Amount % Total Revenues
decrease in total revenue 3.4% and can be summarized as following table. Description Total Revenue (MB) Y-O-Y Change Increase/(Decrease) Note 2016 2017 Sales 919.8 882.2 -4.1% The sales volume decreases as
/2017 and Q3/2016 in which generate constant growth of revenue and can be summarized as following table. Description Total Revenue (MB) Y-O-Y Change Increase/(Decrease) Note Q3/2016 Q3/2017 Sales 248.3
results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
for the three-month period of year 2018 and 2017 Unit: Million Baht Q1’2018 Q1’2017 Increase (Decrease) % Change Sales income 14,874.75 14,270.69 604.06 4.23% Rental and service income 499.08 481.06
Quarter 3 2017 Increase / (Decrease) % Change Revenues from sales 157.19 77.29 79.90 103.38% Other revenues 0.18 0.34 (0.16) (47.06%) Total revenues 157.37 77.63 79.74 102.72% Cost of sales 57.43 31.62
) Consolidated * 2018 2017 Increase / (Decrease) % Change Revenues from sales 666.36 387.35 279.01 103.38% Other revenues 6.76 1.21 5.54 458.11% Total revenues 673.12 388.56 284.55 73.23% Cost of sales 256.50
86.71 million, with significant operating results as follows. (Million Baht) 2019 2018 Increase /(decrease) %change Revenues from sales 789.92 666.36 123.56 18.54% Other revenues 7.58 6.76 0.82 12.13